Journal Of Stuff Beyond
#Psychiatry
June 2026. Volume 1, Issue 5
The Ollivander Phenomenon: Choosing the Right Drug for the Right Patient, and Why the Drug Sometimes Chooses the Patient
When Harry Potter first walks into Ollivanders, he expects to buy a wand the way he might buy a quill. Instead the old wandmaker tells him the relationship works the other way round. The wand senses some affinity that it alone can feel, and the wand picks him. Harry tries many wands. Most do nothing, and some make things worse. Only one gives off the warmth and the sparks of a real match. It is a useful and slightly playful image for a problem that sits close to the heart of clinical psychiatry. We talk about choosing a drug for a patient as if the choice ran one way and the patient just sat there. But even the most carefully evidence-based choice can fall flat, or do harm, in a given person, while a less obvious one can suddenly come to life. In a real sense, the drug chooses the patient too.
The simile is chosen on purpose. Efficacy shown in a trial population is a statement about the average of a group, whereas the patient sitting in front of us is one particular person, with their own physiology, beliefs and temperament, all of which decide whether the match holds. We use amitriptyline as our example because it captures the problem so well. It genuinely works, yet it carries so many adverse effects that it is often the wrong wand for the wizard.
The candidate molecule: amitriptyline
Amitriptyline is a tricyclic antidepressant (TCA) that blocks the reuptake of both serotonin and noradrenaline. It is approved for depression in adults, but these days it is used far more often off-label: for chronic pain, diabetic and post-herpetic neuropathy, fibromyalgia, migraine prevention, irritable bowel syndrome and insomnia. Its pain-relieving and sedating effects at low doses keep it useful decades after newer drugs arrived.
The trouble is that its pharmacology is far from clean. On top of the intended action on monoamines, amitriptyline also has anticholinergic, antihistaminic and alpha-adrenergic blocking effects, and together these produce its familiar list of side effects. To borrow the wandlore image, it is a powerful instrument with a temper of its own. It suits some hands and fights against others.
Efficacy weighed against safety
Nobody really doubts that amitriptyline works. The questions are about how well it is tolerated and how safe it is. It is no longer a first-line treatment for depression precisely because its side-effect load is heavy. Instead it tends to be kept for severe or treatment-resistant depression, or for patients who also have chronic pain or insomnia, where the sedation and pain relief become an advantage rather than a problem.
The common side effects are dry mouth, blurred vision, drowsiness, dizziness, constipation, difficulty passing urine, weight change and a drop in blood pressure on standing. The more serious worries include QT prolongation and the risk of dangerous heart rhythms, which make it a poor choice for many patients with cardiac disease, and overdose can be fatal. It can bring on or worsen narrow-angle glaucoma, and like other antidepressants it can tip a vulnerable patient into mania. The American Geriatrics Society Beers Criteria specifically advise against using amitriptyline in older adults because of its strong anticholinergic load.
Choosing badly: the wrong wand for the wizard
Amitriptyline's problem is rarely that it does not work. The problem is giving it to the wrong person. Hand it to a frail older patient, someone with heart disease, or someone at risk of overdose, and an effective drug turns into a dangerous one. Researchers are aware of this, which is why some have run systematic, placebo-controlled meta-analyses across many indications, trying to work out how much of the anticholinergic and other adverse-event burden comes from the drug itself rather than from the underlying illness or from nocebo effects. That effort is itself a quiet admission that the side effects we pin on a molecule belong partly to the patient and the setting.
When the patient shapes the side effects
This is where the Ollivander image really pays off. Two patients given the very same tablet can have very different experiences. Some of that is pharmacogenetics, but a good deal of it is expectation, which can produce symptoms on its own. This is the nocebo effect: expecting harm makes the harm more likely to be felt, and existing or unrelated symptoms get blamed on the new drug. What a patient expects, including the expectations we create during consent and counselling, has a strong effect on the side effects they then notice. A clinician's own doubts about a drug can make this worse.
Suggestibility and expectation
Several psychological traits have been studied as predictors of how a person responds to placebo and nocebo. The evidence here is mixed and should be read with care. Traits such as optimism, empathy and suggestibility have been linked mainly to placebo responses, while pessimism, anxiety and catastrophising have been linked mainly to nocebo responses. Neuroticism is the awkward case. Some experimental work has grouped it with the placebo-linked traits, but across the wider review literature it shows up far more consistently on the nocebo side, which is the finding we return to below. The practical message is simpler than the trait lists suggest. A patient who leaves the consulting room primed to expect a dry mouth and dizziness has, in part, been handed the script for those very symptoms.
Personality
When the focus narrows specifically to side effects and the nocebo response, the picture becomes much clearer. In reviews of nocebo risk factors, neuroticism is the trait most consistently and positively linked with the nocebo response, with pessimism and low optimism not far behind. A recent study went a step further and described how this works. People high in neuroticism report more bodily complaints even before any treatment begins, expect more side effects beforehand, and then show a stronger nocebo response afterwards. Crucially, the link between neuroticism and that response runs partly through those prior expectations rather than being separate from them. So temperament and expectation are not two rival explanations. They are two links in the same chain, and this is the sense in which neuroticism belongs on the nocebo side.
The evidence is not all one way. At least one case-control study found no clear link between neuroticism, health anxiety or common pharmacogenetic variants and self-reported trouble tolerating antidepressants, a reminder that these are tendencies rather than fixed rules. Even so, the broad weight of evidence points to something we can act on in the clinic: who the patient is helps decide whether a drug will suit them.
Prescribing as matching
If side effects are written jointly by the molecule and the patient, then good prescribing looks more like Ollivander's craft than a transaction at a vending machine. Three practical lessons follow. First, look at the wizard, not just the wand. Cardiac status, age, glaucoma and overdose risk are firm reasons to avoid amitriptyline, while temperament and expectation are softer factors that still sway how well it is tolerated. Second, frame expectations with care. Because the wording we use during consent can itself bring on symptoms, how we explain the risks is part of the treatment, not a neutral formality. Third, be ready to try a different wand. A poor match is information, not failure, and the right fit sometimes shows up only on the second or third attempt.
Conclusion
Ollivander's line, that the wand chooses the wizard, is a neat reversal of how we usually imagine authority working. Psychiatry holds the same reversal. Amitriptyline is effective, but its real safety and side-effect burden mean it is the right wand only in certain hands, and even then the patient's expectations, suggestibility and personality help decide whether the match will spark or just smoulder. Our job is not only to choose a drug. It is to recognise when a drug and a patient have chosen each other.
References:
Columbus C (director). Harry Potter and the Philosopher’s Stone [Sorcerer’s Stone]. Warner Bros. Pictures; 2001. Based on the novel by Rowling JK.
Faasse K, Petrie KJ. The nocebo effect: patient expectations and medication side effects. Postgrad Med J. 2013 Sep;89(1055):540-6. doi: 10.1136/postgradmedj-2012-131730. Epub 2013 Jul 10. PMID: 23842213.
Corsi N, Colloca L. Placebo and Nocebo Effects: The Advantage of Measuring Expectations and Psychological Factors. Front Psychol. 2017 Mar 6;8:308. doi: 10.3389/fpsyg.2017.00308. PMID: 28321201; PMCID: PMC5337503.
@psychidiaries